187 related articles for article (PubMed ID: 28645291)
1. The effect of zoledronic acid on type and volume of Modic changes among patients with low back pain.
Koivisto K; Järvinen J; Karppinen J; Haapea M; Paananen M; Kyllönen E; Tervonen O; Niinimäki J
BMC Musculoskelet Disord; 2017 Jun; 18(1):274. PubMed ID: 28645291
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging.
Koivisto K; Kyllönen E; Haapea M; Niinimäki J; Sundqvist K; Pehkonen T; Seitsalo S; Tervonen O; Karppinen J
BMC Musculoskelet Disord; 2014 Mar; 15():64. PubMed ID: 24588905
[TBL] [Abstract][Full Text] [Related]
3. Association between changes in lumbar Modic changes and low back symptoms over a two-year period.
Järvinen J; Karppinen J; Niinimäki J; Haapea M; Grönblad M; Luoma K; Rinne E
BMC Musculoskelet Disord; 2015 Apr; 16():98. PubMed ID: 25897658
[TBL] [Abstract][Full Text] [Related]
4. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial.
Shea GKH; Zhang C; Suen WS; Cheung PWH; Cheung JPY; Maatta J; Karppinen J; Samartzis D
J Orthop Res; 2022 Dec; 40(12):2924-2936. PubMed ID: 35195306
[TBL] [Abstract][Full Text] [Related]
5. Effect of Zoledronic Acid and Denosumab in Patients With Low Back Pain and Modic Change: A Proof-of-Principle Trial.
Cai G; Laslett LL; Aitken D; Halliday A; Pan F; Otahal P; Speden D; Winzenberg TM; Jones G
J Bone Miner Res; 2018 May; 33(5):773-782. PubMed ID: 29297602
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Zoledronic Acid on Serum Biomarkers among Patients with Chronic Low Back Pain and Modic Changes in Lumbar Magnetic Resonance Imaging.
Koivisto K; Karppinen J; Haapea M; Järvinen J; Kyllönen E; Tervonen O; Niinimäki J; Alini M; Lotz J; Dudli S; Samartzis D; Risteli J; Majuri ML; Alenius H; Grad S
Diagnostics (Basel); 2019 Dec; 9(4):. PubMed ID: 31817123
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2
Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
Cancer Immunol Immunother; 2017 Sep; 66(9):1205-1215. PubMed ID: 28501938
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial.
Laslett LL; Doré DA; Quinn SJ; Boon P; Ryan E; Winzenberg TM; Jones G
Ann Rheum Dis; 2012 Aug; 71(8):1322-8. PubMed ID: 22355040
[TBL] [Abstract][Full Text] [Related]
9. Correlation of size and type of modic types 1 and 2 lesions with clinical symptoms: a descriptive study in a subgroup of patients with chronic low back pain on the basis of a university hospital patient sample.
Kääpä E; Luoma K; Pitkäniemi J; Kerttula L; Grönblad M
Spine (Phila Pa 1976); 2012 Jan; 37(2):134-9. PubMed ID: 21415809
[TBL] [Abstract][Full Text] [Related]
10. Does bone scintigraphy show Modic changes associated with increased bone turnover?
Järvinen J; Niinimäki J; Karppinen J; Takalo R; Haapea M; Tervonen O
Eur J Radiol Open; 2020; 7():100222. PubMed ID: 32071952
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
Westin JR; Thompson MA; Cataldo VD; Fayad LE; Fowler N; Fanale MA; Neelapu S; Samaniego F; Romaguera J; Shah J; McLaughlin P; Pro B; Kwak LW; Sanjorjo P; Murphy WA; Jimenez C; Toth B; Dong W; Hagemeister FB
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):99-105. PubMed ID: 23276888
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study.
Clive AO; Hooper CE; Edey AJ; Morley AJ; Zahan-Evans N; Hall D; Lyburn I; White P; Braybrooke JP; Sequeiros I; Lyen SM; Milton T; Kahan BC; Maskell NA
PLoS One; 2015; 10(3):e0118569. PubMed ID: 25781025
[TBL] [Abstract][Full Text] [Related]
13. Effect of zoledronic acid in an L6-L7 rabbit spine fusion model.
Bransford R; Goergens E; Briody J; Amanat N; Cree A; Little D
Eur Spine J; 2007 Apr; 16(4):557-62. PubMed ID: 16967298
[TBL] [Abstract][Full Text] [Related]
14. Serum biomarkers for Modic changes in patients with chronic low back pain.
Karppinen J; Koivisto K; Ketola J; Haapea M; Paananen M; Herzig KH; Alini M; Lotz J; Dudli S; Samartzis D; Risteli J; Majuri ML; Alenius H; Kyllönen E; Järvinen J; Niinimäki J; Grad S
Eur Spine J; 2021 Apr; 30(4):1018-1027. PubMed ID: 33423134
[TBL] [Abstract][Full Text] [Related]
15. Fracture risk and zoledronic acid therapy in men with osteoporosis.
Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
[TBL] [Abstract][Full Text] [Related]
16. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
17. Association of Modic change types and their short tau inversion recovery signals with clinical characteristics- a cross sectional study of chronic low back pain patients in the AIM-study.
Bråten LCH; Schistad EI; Espeland A; Kristoffersen PM; Haugen AJ; Marchand GH; Vetti N; Pripp AH; Kadar TI; Skouen JS; Grotle M; Grøvle L; Zwart JA; Brox JI; Storheim K;
BMC Musculoskelet Disord; 2020 Jun; 21(1):368. PubMed ID: 32522268
[TBL] [Abstract][Full Text] [Related]
18. Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.
Ripamonti C; Fagnoni E; Campa T; Giardina V; Brunelli C; Pigni A; De Conno F
Support Care Cancer; 2007 Oct; 15(10):1177-84. PubMed ID: 17333295
[TBL] [Abstract][Full Text] [Related]
19. Markers of inflammation after zoledronic acid redosing.
Sykiotis A; Papaioannou G; Mavropoulos J; Triantaphyllopoulou M; Papandroulaki F; Ktena V; Thanou S; Pardalakis A; Kaltsa A; Karga H
J Bone Miner Metab; 2014 Jan; 32(1):72-7. PubMed ID: 23690161
[TBL] [Abstract][Full Text] [Related]
20. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
